Curriculum vitae

INFORMAZIONI PERSONALI

Gionata Fiorino

via Gaetano Storchi 16, 00151 Roma

gionataf@gmail.com

FRNGNT79R24F262F

Sesso Maschio

Data di nascita 24/10/1979

Nazionalità Italiana

Posizione lavorativa

Responsabile della Ricerca Clinica in IBD

UOS Malattie Infiammatorie Croniche Intestinali, Unità Operativa Complessa di Gastroenterologia ed Endoscopia Digestiva Diagnostica ed Operativa, Ospedale San Camillo-Forlanini, Roma (Italia)

Responsabile della gestione dei trials clinici e della ricerca scientifica in inflammatory bowel disease (IBD)

Esperienza lavorativa

15/11/2021-31/12/2023

Gastroenterologo consulente

Dipartimento di Gastroenterologia ed Endoscopia Digestiva, Ospedale San Raffaele, Milano (Italia)

Attività clinica ambulatoriale in presenza e in telemedicina su pazienti affetti da patologie gastrointestinali, in particolare IBD

15/11/2021-15/11/2023

Professore a contratto in Gastroenterologia – Università Vita-Salute San Raffaele, Milano, Italia

Docenza (lezioni ed esami di profitto) in Gastroenterologia dei corsi di laurea magistrale in Medicina e Chirurgia e International Medical Doctor Program

Docenza in Terapia Medica del corso di laurea magistrale in Medicina e Chirurgia

Tutor degli specializzandi in Gastroenterologia del primo anno accademico.

17/06/2019–14/11/2021

Ricercatore Universitario in Gastroenterologia - RDTA

Dipartimento di Scienze Biomediche, Humanitas University, Pieve Emanuele, Milano (Italia)

Docenza nel corso di laurea in Medicina e Chirurgia e attività scientifica

01/01/2017–17/06/2019

Aiuto Gastroenterologo, specialista in IBD

IBD Center, IRCCS Humanitas, Rozzano (Italia)

Gestione clinica dei pazienti con IBD. Ricerca clinica in IBD.

28/07/2017–17/06/2019 **Professore a contratto in Gastroenterologia**

Dipartimento di Scienze Biomediche, Humanitas University, Pieve Emanuele, Milano (Italia)

Docenza in Gastroenterologia nel corso di laurea in Medicina e Chirurgia e attività scientifica

01/01/2010–31/12/2016 **Assistente in Gastroenterologia, specialista in IBD**

IBD Center, Dept. of Gastroenterology, IRCCS Humanitas, Rozzano (Italia)

Gestione clinica dei pazienti con IBD. Ricerca clinica in IBD.

01/09/2008–30/04/2009 **Fellow in Ricerca Clinica**

IRCCS Humanitas. Rozzano (Italia)

Ricerca clinica in IBD.

01/05/2005–31/08/2008 **Sostituto Medico di Medicina Generale**

00100 Roma (Italia)

Medicina generale

EDUCATION AND TRAINING

01/01/2010–31/12/2012 **Philosophiae Doctor**

Università di Messina, Messina (Italia)

Epatogastroenterologia dell'età evolutiva e dell'adulto

Livello 6 ISCED

01/11/2005–19/11/2009 **Specialista in Gastroenterologia**

Sapienza, Università di Roma, Roma (Italia)

Gastroenterologia

Livello 6 ISCED

19/10/1998–28/10/2004 **Laurea in Medicina e Chirurgia**

Università Cattolica del Sacro Cuore - Roma

Largo Gemelli 1, 00168 Roma (Italia)

Livello 5B ISCED

01/09/1993–31/07/1998 **Licenza liceale**

Liceo Classico "Cagnazzi"

Piazza Zanardelli, 70022 Altamura (Italia)

	Livello 3B ISCED
19/10/2017–20/10/2017	Corso Avanzato di Management in Gastroenterologia e Immunologia
	EQF level 8
	LIUC University, Castellanza (Italia)
	- *Gestione delle risorse sanitarie, impatto sul budget*
	- *Capacità di presentazione e negoziazione*
	- *Aspetti legali nella pratica clinica*
11/2011–03/2012	Corso avanzato su revisioni sistematiche, metanalisi e produzione linee guida.
	Cochrane Collaboration, Istituto Mario Negri - Università di Milano, Milano (Italia)
	- *Revisione sistematica*
	- *Ricerca di letteratura*
	- *Valutazione della qualità dei dati*
	- *Estrazione e meta-analisi dei dati*
	- *Metodologia GRADE*
	- *Valutazione dell'evidenza scientifica*
	- *Produzione di consenso e linee guida*
09/2008	Master Class in Crohn's Disease
	Experimental Medicine Division - Università di Oxford, Oxford (United Kingdom)
	Corso intensivo di diagnostica e gestione terapeutcia della malattia di Crohn
09/2007	Master Class in Ulcerative Colitis
	Experimental Medicine Division - Università di Oxford, Oxford (United Kingdom)
	Corso intensivo di diagnostica e gestione terapeutcia della colite ulcerosa
04/2007–06/2007	Corso Avanzato di Endoscopia e Videocapsula Endoscopia.
	Università Cattolica del Sacro Cuore, Roma (Italia)
09/2004–10/2004	Training in Gastroenterologia, Endoscopia Digestiva e Proctologia
	Bichat-Claude Bernard Hospital, Paris (France)
03/2004	Training in Gastroenterologia, Endoscopia Digestiva e Proctologia
	Bichat-Claude Bernard Hospital, Paris (France)
06/09/2003–31/10/2003	Training in Gastroenterologia, Endoscopia Digestiva e Proctologia
	Bichat-Claude Bernard Hospital, Paris (France)
19/09/2002–19/10/2002	Training in Gastroenterologia, Endoscopia Digestiva e Proctologia

Bichat-Claude Bernard Hospital, Paris (France)

COMPETENZE PERSONALI

Lingua madre: Italiano

Lingue straniere

	COMPRENSIONE		PARLATA		SCRITTA
	Ascolto	Lettura	Comprensione	Capacità di parlare	
Inglese	C1	C2	C1	C1	C2
Francese	B2	B2	B1	B1	A2
Spagnolo	B2	B2	A2	A2	A2
Olandese	A1	A2	A1	A2	A2

Livelli: A1 e A2: Base - B1 e B2: Indipendente - C1 e C2: Fluente

Common European Framework of Reference for Languages – Self-assessment grid

Capacità di comunicazione

2010-oggi: Relatore e Membro della Faculty in più di 100 Congressi Nazionali e Internazionali nel campo delle malattie infiammatorie croniche intestinali

N. 2 presentazioni orali alla Digestive Disease Week (DDW) – Stati Uniti

N. 3 presentazioni orali al Congresso della European Crohn's Colitis Organisation (ECCO)

Abilità organizzative

Organizzazione e coordinamento di gruppi di lavoro e studi clinici collaborativi nazionali e internazionali.

Coordinamento delle linee guida nazionali e internazionali.

Competenze informatiche

Microsoft Windows, Office e gestione di banche dati elettroniche.

Utilizzo di software statistici (SPSS, Jamovi, MedCalc)

INFORMAZIONI AGGIUNTIVE

Premi e Grants

2022: Grant di ricerca Galapagos Global dal titolo “Comparison between Bowel Ultrasound-based Treat to Target Versus Routine Treat to Target Strategies in Ulcerative Colitis” – Euro 300.000

2019: Pfizer research grant INNOVARE su "Lipid profiles in patients with ulcerative colitis treated with tofacitinib profile: understanding the mechanism of action." Euro 50.000

2017 ECCO Vifor Grant su "Efficacy of iron supplementation in patients with inflammatory bowel disease and chronic fatigue" - Euro 40.000

2014: Best abstract, Digital Oral Poster Presentation, Session 4, ECCO Congress, Copenhagen (DK)

Certificazioni

10/04/2017-10/04/2027: Abilitazione Scientifica Nazionale a Professore Associato in Gastroenterologia - MIUR – Italia

Progetti principali

2021-2026: Coordinatore del progetto ECCO E-QUALITY sugli standard di cura nelle IBD

Identificazione di gaps tra standard di qualità proposti dalla European Crohn’s Colitis Organisation (ECCO) e la pratica clinica a livello europeo ed extra-europeo

2023: Linee guida ECCO basate su GRADE sulla terapia nella malattia di Crohn

2020-2021: Linee guida ECCO su Gravidanza e Allattamento nelle IBD

2020-2021: Leader del gruppo di lavoro nelle linee guida ECCO su tumori maligni e IBD

2019-2021: Linee guida ECCO basate su GRADE sulla terapia nella colite ulcerosa

2019-2022: Membro del Consensus Panel sulle linee guida IG-IBD basate su GRADE sulla terapia biologica nelle malattie infiammatorie intestinali

2018-2020: Coordinatore del progetto ECCO: "Quality of Standards of Care in IBD"

Revisione sistematica e coordinamento di una Consensus internazionale per definire gli standard di qualità delle cure nei pazienti con IBD

2018-in corso: Coordinatore del Registro Nazionale sui Biosimilari nelle IBD per conto del Gruppo Italiano per le IBD (IG-IBD)

Ottobre 2017-2020: Coordinatore delle Linee guida ECCO basate su GRADE sulla terapia nella malattia di Crohn

Marzo 2017-in corso: e-Guide Champion per l'ECCO

Principal Investigator nel trial randomizzato controllato multicentrico europeo A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic Crohn’s disease recurrence EUDRACT 2017-002258-36

Ottobre 2016-Ottobre 2017: Working Group leader per l'ECCO "Diagnostic and Monitoring Consensus"

2014 - Bibliographic Fellow per la International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) Progetto STRIDE (Selezione di bersagli terapeutici nelle malattie infiammatorie intestinali)

2010 - Principal investigator nello studio di validazione dell'indice di gravità endoscopica della colite ulcerosa (UCEIS)

2010 – World Health Organisation Consensus Conference su "ICF Core Sets for IBD" – Nottwil (CH)

2008-in corso Sub-investigatore in più di 150 studi clinici randomizzati multicentrici di fase 1-4 sulle malattie infiammatorie intestinali

Incarichi a carattere scientifico

Marzo 2023-oggi: Educational Officer della European Crohn's Colitis Organisation (ECCO)

Responsabile delle attività formative della European Crohn's Colitis Organisation

Marzo 2023-oggi: Membro del Governing Board della European Crohn's Colitis Organisation (ECCO)

Agosto 2018-oggi: Associate Editor del Journal of Crohn's and Colitis (JCC) – Impact Factor 10,02

Gennaio 2018-2021: Chair del Comitato Scientifico del Gruppo Italiano di Malattie Infiammatorie Intestinali (IG-IBD)

Coordinamento degli studi clinici multicentrici promossi dalla IG-IBD a livello italiano

Ottobre 2016-Marzo 2019: Membro ECCO CONFER

Coordinamento di studi clinici su casistiche di eventi rari in malattie infiammatorie croniche intestinali

Febbraio 2015-Febbraio 2018: Membro del Comitato delle Linee guida (GuiCom) della European Crohn's Colitis Organisation (ECCO)

Coordinamento delle linee guida ECCO su malattie infiammatorie croniche intestinali

Febbraio 2015-luglio 2018: Membro dell'Editorial Board del Journal of Crohn's and Colitis (JCC)

Gennaio 2014-gennaio 2017: Membro del Comitato Scientifico del Gruppo Italiano Malattie Infiammatorie Intestinali (IG-IBD)

3 aprile 2014: Membro del Consensus International Organization -IBD "Treat to Target"

Ottobre 2006 - Marzo 2009 Presidente della Young European Crohn's Colitis Organization (Y-ECCO)

Memberships

2006-oggi: Membro dell'European Crohn's Colitis Organisation (ECCO)

2006-in corso: Membro del Gruppo Italiano - Malattie Infiammatorie Intestinali (IG-IBD)

2005-2009: Membro della Società Italiana di Gastroenterologia ed Endoscopia Digestiva (SIGE)

19 luglio 2012-in corso: Licenza Medica - OMCEO Milano n. 42409

30 marzo 2005-19 luglio 2012: Licenza Medica - OMceO Bari n. 12903

H-Index 52

(Scopus, 11/01/2024)

Pubblicazioni

1) Cortesi PA, **Fiorino G**, Mantovani LG,Danese S. Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay? Authors' reply. **Aliment Pharmacol Ther** *2023;57(5):571-572*

2) Cortesi PA, **Fiorino G**, Peyrin-Biroulet L, Mantovani LG, Jairath V, Paridaens K, Andersson FL,Danese S. Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis. **Aliment Pharmacol Ther** *2023;57(5):486-495*

3) Torres J, Chaparro M, Julsgaard M, Katsanos K, Zelinkova Z, Agrawal M, Ardizzone S, Campmans-Kuijpers M, Dragoni G, Ferrante M, **Fiorino G**, Flanagan E, Gomes CF, Hart A, Hedin CR, Juillerat P, Mulders A, Myrelid P, O'Toole A, Riviere P, Scharl M, Selinger CP, Sonnenberg E, Toruner M, Wieringa J,Van der Woude CJ. European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. **Journal of Crohn's & colitis** *2023;17(1):1-27*

4) Mandarino FV, Barchi A, D'Amico F, Fanti L, Azzolini F, Viale E, Esposito D, Rosati R, **Fiorino G**, Bemelman WA, Elmore U, Barbieri L, Puccetti F, Testoni SGG,Danese S. Endoscopic Vacuum Therapy (EVT) versus Self-Expandable Metal Stent (SEMS) for Anastomotic Leaks after Upper Gastrointestinal Surgery: Systematic Review and Meta-Analysis. **Life (Basel)** *2023;13(2):*

5) Bergamaschi G, Castiglione F, D'Inca R, Astegiano M, Fries W, Milla M, Ciacci C, Rizzello F, Saibeni S, Ciccocioppo R, Orlando A, Bossa F, Principi M, Vernia P, Ricci C, Scribano ML, Bodini G, Mazzucco D, Bassotti G, Riegler G, Buda A, Neri M, Caprioli F, Monica F, Manca A, Villa E, **Fiorino G**, Comberlato M, Aronico N, Della Corte C, Caccaro R, Gionchetti P, Giuffrida P, Iovino P, Lenti MV, Mengoli C, Pellegrini L, Pieraccini A, Ribaldone D, Testa A, Ubezio C, Viola A, Vecchi M, Klersy C,Di Sabatino A. Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. **Inflamm Bowel Dis** *2023;29(1):76-84*

6) Massimino L, Palmieri O, Facoetti A, Fuggetta D, Spano S, Lamparelli LA, D'Alessio S, Cagliani S, Furfaro F, D'Amico F, Zilli A, **Fiorino G**, Parigi TL, Noviello D, Latiano A, Bossa F, Latiano T, Pirola A, Mologni L, Piazza RG, Abbati D, Perri F, Bonini C, Peyrin-Biroulet L, Malesci A, Jairath V, Danese S,Ungaro F. Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo. **Gut** *2023;*Epub ahead of print

7) Macaluso FS, Principi M, Facciotti F, Contaldo A, Todeschini A, Saibeni S, Bezzio C, Castiglione F, Nardone OM, Spagnuolo R, Fantini MC, Riguccio G, Caprioli F, Vigano C, Felice C, **Fiorino G**, Correale C, Bodini G, Milla M, Scardino G, Vernero M, Desideri F, Mannino M, Rizzo G, Orlando A,Italian Group for the study of Inflammatory Bowel D. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2023;55(2):154-159*

8) D'Amico F, Tasopoulou O, **Fiorino G**, Zilli A, Furfaro F, Allocca M, Sileri P, Spinelli A, Peyrin-Biroulet L,Danese S. Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. **Inflamm Bowel Dis** *2023;29(4):539-547*

9) Dragoni G, Castiglione F, Bezzio C, Pugliese D, Spagnuolo R, Viola A, Cocomazzi F, Aratari A, Savarino EV, Balestrieri P, Onali S, Vigano C, Ribaldone DG, Innocenti T, Testa A, Saibeni S, Privitera G, Milla M, Armuzzi A, Fantini MC,**Fiorino G**. Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study. **United European gastroenterology journal** *2023;11(3):271-281*

10) Macaluso FS, Papi C, Orlando A, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, **Fiorino G**, Fantini MC, Caprioli F, Daperno M, Armuzzi A, Italian Group for the Study of Inflammatory Bowel D, Working p,Review p. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2023;55(4):442-453*

11) D'Amico F, **Fiorino G**, Solitano V, Massarini E, Guillo L, Allocca M, Furfaro F, Zilli A, Bonovas S, Magro F, Peyrin-Biroulet L,Danese S. Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study. **United European gastroenterology journal** *2022;10(7):775-782*

12) D'Amico F, Danese S,**Fiorino G**. Could small molecules be used in combination with biologics for inflammatory bowel disease? **Expert Rev Clin Immunol** *2022;18(10):991-993*

13) **Fiorino G**, Danese S, Peyrin-Biroulet L, Sans M, Bonelli F, Calleri M, Zierold C, Pollastro R, Moretti F,Malesci A. LIAISON((R)) Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. **United European gastroenterology journal** *2022;10(8):836-843*

14) D'Amico F, Allocca M,**Fiorino G**. Positioning Ozanimod in Ulcerative Colitis: Restoring Leukocyte Traffic Under Control. **Gastroenterology** *2022;162(6):1767-1769*

15) D'Amico F, Zilli A,**Fiorino G**. Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives? **United European gastroenterology journal** *2022;10(2):141-142*

16) Allocca M, Dell'Avalle C, Craviotto V, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, **Fiorino G**,Danese S. Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. **United European gastroenterology journal** *2022;10(2):190-197*

17) Furfaro F, Dal Buono A, Sicuso C, Allocca M, D'Amico F, Zilli A, **Fiorino G**, Gabbiadini R,Danese S. Carcinomas in inflammatory bowel disease: a narrative review on diagnostic imaging techniques. **Chin Clin Oncol** *2022;11(3):22*

18) Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, **Fiorino G**, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A,Group I-ILS. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. **Aliment Pharmacol Ther** *2022;56(1):95-109*

19) Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, **Fiorino G**, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Spinelli A, Panis Y,Doherty G. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. **Journal of Crohn's & colitis** *2022;16(1):2-17*

20) Solitano V, Zilli A, Franchellucci G, Allocca M, **Fiorino G**, Furfaro F, D'Amico F, Danese S,Al Awadhi S. Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future. **Journal of clinical medicine** *2022;11(3):*

21) Gabbiadini R, D'Amico F, De Marco A, Terrin M, Zilli A, Furfaro F, Allocca M, **Fiorino G**,Danese S. Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question. **Journal of clinical medicine** *2022;11(3):*

22) Alfarone L, Dal Buono A, Craviotto V, Zilli A, **Fiorino G**, Furfaro F, D'Amico F, Danese S,Allocca M. Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows. **Journal of clinical medicine** *2022;11(2):*

23) Mazza S, Piazza OSN, Conforti FS, Fasci A, Rimondi A, Marinoni B, Casini V, Ricci C, Munari F, Pirola L, Invernizzi P, Girelli C, Lupinacci G, Pastorelli L, Cavallaro F, Ferraris L, Colucci A, Amato A, Eugenio Tontini G, Vecchi M, **Fiorino G**,Caprioli F. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. **Clin Transl Sci** *2022;15(1):172-181*

24) Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, **Fiorino G**, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Doherty G, Raine T,Panis Y. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. **Journal of Crohn's & colitis** *2022;16(2):179-189*

25) Vespa E, D'Amico F, Sollai M, Allocca M, Furfaro F, Zilli A, Dal Buono A, Gabbiadini R, Danese S,**Fiorino G**. Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. **Journal of clinical medicine** *2022;11(4):*

26) Parigi TL, Mastrorocco E, Da Rio L, Allocca M, D'Amico F, Zilli A, **Fiorino G**, Danese S,Furfaro F. Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases. **Journal of clinical medicine** *2022;11(3):*

27) Allocca M, Craviotto V, Dell'Avalle C, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, **Fiorino G**,Danese S. Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. **Aliment Pharmacol Ther** *2022;55(4):446-454*

28) Dell'Avalle C, D'Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, **Fiorino G**, Allocca M, Peyrin-Biroulet L,Danese S. JAK inhibitors in crohn's disease: ready to go? **Expert opinion on investigational drugs** *2022;31(2):145-161*

29) Gordon H, Biancone L, **Fiorino G**, Katsanos KH, Kopylov U, Sulais EA, Axelrad JE, Balendran K, Burisch J, de Ridder L, Derikx L, Ellul P, Greuter T, Iacucci M, Di Jiang C, Kapizioni C, Karmiris K, Kirchgesner J, Laharie D, Lobaton Ortega T, Molnar T, Noor NM, Rao R, Saibeni S, Scharl M, Vavricka SR,Raine T. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. **Journal of Crohn's & colitis** *2022;*Epub ahead of print

30) Furfaro F, D'Amico F, Zilli A, Craviotto V, Aratari A, Bezzio C, Spinelli A, Gilardi D, Radice S, Saibeni S, Papi C, Peyrin-Biroulet L, Danese S, **Fiorino G**,Allocca M. Noninvasive Assessment of Postoperative Disease Recurrence in Crohn's Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease. **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2022;*Epub ahead of print

31) Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, **Fiorino G**, Drobne D, Kurent T, Yassin S, Maharshak N, Castiglione F, de Sire R, Nardone OM, Farkas K, Molnar T, Krznaric Z, Brinar M, Chashkova E, Livne Margolin M, Kopylov U, Bezzio C, Bar-Gil Shitrit A, Lukas M, Chaparro M, Truyens M, Nancey S, Lobaton T, Gisbert JP, Saibeni S, Bacsur P, Bossuyt P, Schulberg J, Hoentjen F, Vigano C, Palermo A, Torres J, Reves J, Karmiris K, Velegraki M, Savarino E, Markopoulos P, Tsironi E, Ellul P, Calvino Suarez C, Weisshof R, Ben-Hur D, Naftali T, Eriksson C, Koutroubakis IE, Foteinogiannopoulou K, Limdi JK, Liu E, Suris G, Calabrese E, Zorzi F, Filip R, Ribaldone DG, Snir Y, Goren I, Banai-Eran H, Broytman Y, Amir Barak H, Avni-Biron I, Ollech JE, Dotan I,Aharoni Golan M. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. **Journal of Crohn's & colitis** *2022;16(12):1882-1892*

32) Sciberras M, Karmiris K, Nascimento C, Tabone T, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris GJ, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, **Fiorino G**, Furfaro F, Katsanos K, Fousekis F, Michalopoulos G, Camilleri L, Torres J,Ellul P. Mental Health, Work Presenteeism, and Exercise in Inflammatory Bowel Disease. **Journal of Crohn's & colitis** *2022;16(8):1197-1201*

33) Torres J, Chaparro M, Julsgaard M, Katsanos K, Zelinkova Z, Agrawal M, Ardizzone S, Campmans-Kuijpers M, Dragoni G, Ferrante M, **Fiorino G**, Flanagan E, Frias Gomes C, Hart A, Hedin CR, Juillerat P, Mulders A, Myrelid P, O'Toole A, Riviere P, Scharl M, Selinger CP, Sonnenberg E, Toruner M, Wieringa J,Van der Woude CJ. European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. **Journal of Crohn's & colitis** *2022;*Epub ahead of print

34) Bezzio C, **Fiorino G**, Ribaldone DG, Armuzzi A, Saibeni S,Group I-IC-S. IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame. **Inflamm Bowel Dis** *2022;*Epub ahead of print

35) Ellul P, Reves J, Abreu B, Chaparro M, Gisbert JP, Allocca M, **Fiorino G**, Barberio B, Zingone F, Pisani A, Cassar D, Michalopoulos G, Mantzaris G, Koutroubakis I, Karmiris K, Katsanos K, Duricova D, Burisch J, Madsen GR, Maaser C, Naila A, Orfanoudaki E, Milivojevic V, Buisson A, Avedano L, Leone S,Torres J. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey. **Journal of Crohn's & colitis** *2022;16(7):1070-1078*

36) Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, Imperatore N, **Fiorino G**, Cappello M, Viola A, Principi MB, Bezzio C, Aratari A, Carparelli S, Mazzuoli S, Manguso F, Grossi L, Bodini G, Ribaldone D, Mocci G, Miranda A, Minerba L, Favale A, Grova M, Scucchi L, Segato S, Fries W, Castiglione F, Armuzzi A, Fantini MC,Ig IBD. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. **The American journal of gastroenterology** *2022;117(8):1279-1287*

37) Allocca M, Craviotto V, Bonovas S, Furfaro F, Zilli A, Peyrin-Biroulet L, **Fiorino G**,Danese S. Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2022;20(4):e723-e740*

38) Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, **Fiorino G**, Fantini MC, Caprioli F, Daperno M, Armuzzi A, Italian Group for the Study of Inflammatory Bowel D, Working p,Review p. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. **Digestive and liver disease : official journal of the Italian Society of**

Gastroenterology and the Italian Association for the Study of the Liver *2022;54(4):440-451*

39) Furfaro F, Gabbiadini R, D'Amico F, Zilli A, Dal Buono A, Allocca M, **Fiorino G**,Danese S. Gastrointestinal System: COVID-19 and Potential Mechanisms Associated with Coagulopathy. **Curr Drug Targets** *2022;23(17):1611-1619*

40) **Fiorino G**,Danese S. The new frontier: Certifying quality standards in the inflammatory bowel disease care. **United European gastroenterology journal** *2021;9(7):745-747*

41) Adamina M,**Fiorino G**. At the Crossroads of Caution and Intervention: Anti-TNF Therapy Prior to Elective CD Surgery. **Journal of Crohn's & colitis** *2021;15(10):1778-1779*

42) **Fiorino G**, Allocca M,Danese S. Adalimumab biosimilar in inflammatory bowel disease. **The lancet. Gastroenterology & hepatology** *2021;6(10):775-776*

43) Napolitano D, Scaldaferri F, **Fiorino G**, Spagnuolo R, Leonetti A, Lopetuso LR,Cocchieri A. Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey. **Gastroenterol Nurs** *2021;44(3):E59-E66*

44) Viola A, **Fiorino G**, Costantino G,Fries W. Epidemiology and clinical course of late onset inflammatory bowel disease. **Minerva Gastroenterol (Torino)** *2021;*Epub ahead of print

45) Allocca M, Filippi E, Costantino A, Bonovas S, **Fiorino G**, Furfaro F, Peyrin-Biroulet L, Fraquelli M, Caprioli F,Danese S. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. **United European gastroenterology journal** *2021;9(4):438-442*

46) Spagnuolo R, Corea A, Napolitano D, Nistico E, Pagnotta R, Pagliuso C, Schiavoni E, Turchini L, **Fiorino G**, Radice S, Armuzzi A,Doldo P. Nursing-sensitive outcomes in adult inflammatory bowel disease: A systematic review. **Journal of advanced nursing** *2021;77(5):2248-2266*

47) Ribaldone DG, Imperatore N, Le Grazie M, Furfaro F, Balestrieri P, De Blasio F, Fagoonee S, Mosso E, Boano V, Reggio D, Sarli E, Castiglione F, Milla M, Vecchi M, Saracco GM, Salizzoni M, Romagnoli R, **Fiorino G**, Astegiano M,Italian Group for the study of Inflammatory Bowel Disease I-I. Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2021;53(6):712-716*

48) Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, **Fiorino G**, Danese S,Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. **World J Gastroenterol** *2021;27(27):4276-4297*

49) Allocca M, Furfaro F, **Fiorino G**, Peyrin-Biroulet L,Danese S. Point-of-Care Ultrasound in Inflammatory Bowel Disease. **Journal of Crohn's & colitis** *2021;15(1):143-151*

50) Ruiz-Casas L, Evans J, Rose A, Pedra GG, Lobo A, Finnegan A, Hayee B, Peyrin-Biroulet L, Sturm A, Burisch J, Terry H, Avedano L, Tucknott S, **Fiorino G**,Limdi J. Correction to: The LUCID study: living with ulcerative colitis: identifying the socioeconomic burden in Europe. **BMC Gastroenterol** *2021;21(1):475*

51) Loy L, **Fiorino G**, Roda G, Allocca M, Furfaro F, Zilli A, Gilardi D, Radice S, Peyrin-Biroulet L,Danese S. New Paradigms to Help Decisions in Treatment

Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. **Curr Drug Targets** *2021;22(4):370-378*

52) Ruiz-Casas L, Evans J, Rose A, Pedra GG, Lobo A, Finnegan A, Hayee B, Peyrin-Biroulet L, Sturm A, Burisch J, Terry H, Avedano L, Tucknott S, **Fiorino G**,Limdi J. The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe. **BMC Gastroenterol** *2021;21(1):456*

53) Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Vigano C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, **Fiorino G**, Saibeni S,Italian Group for the Study of Inflammatory Bowel D. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. **Aliment Pharmacol Ther** *2021;54(11-12):1432-1441*

54) **Fiorino G**, Danese S, Giacobazzi G,Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2021;53(4):403-408*

55) Solitano V, **Fiorino G**, D'Amico F, Peyrin-Biroulet L,Danese S. Thrombosis in IBD in the Era of JAK Inhibition. **Curr Drug Targets** *2021;22(1):126-136*

56) Gabbiadini R, Zacharopoulou E, Furfaro F, Craviotto V, Zilli A, Gilardi D, Roda G, Loy L, **Fiorino G**, Peyrin-Biroulet L, Danese S,Allocca M. Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality? **Curr Drug Targets** *2021;22(3):347-355*

57) Furfaro F, Alfarone L, Gilardi D, Correale C, Allocca M, **Fiorino G**, Argollo M, Zilli A, Zacharopoulou E, Loy L, Roda G,Danese S. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. **Curr Drug Targets** *2021;22(7):760-769*

58) **Fiorino G**, Estevinho MM, Lopes DJM, Chersi F, Allocca M, Souto MT, Danese S,Magro F. Inflammatory Bowel Disease in Migrant Populations: Should we Look Even Further Back? **Curr Drug Targets** *2021;22(15):1706-1715*

59) Solitano V, D'Amico F, Allocca M, **Fiorino G**, Zilli A, Loy L, Gilardi D, Radice S, Correale C, Danese S, Peyrin-Biroulet L,Furfaro F. Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? **Therapeutic advances in gastroenterology** *2021;14(17562848211005692*

60) Noviello D, Mager R, Roda G, Borroni RG, **Fiorino G**,Vetrano S. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. **Front Immunol** *2021;12(611256*

61) Torres J, Bonovas S,**Fiorino G**. Proactive TDM for Crohn's Disease Patients in Clinical Remission Under Anti-TNF Treatment: Current State of Evidence. **Journal of Crohn's & colitis** *2020;14(9):1338-1339*

62) **Fiorino G**, Allocca M, Furfaro F, Gilardi D, Zilli A, Radice S, Spinelli A,Danese S. Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. **Journal of Crohn's & colitis** *2020;14(9):1330-1333*

63) Solitano V, D'Amico F, **Fiorino G**, Paridaens K, Peyrin-Biroulet L,Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. **Journal of clinical medicine** *2020;9(9):*

64) **Fiorino G**, Lytras T, Younge L, Fidalgo C, Coenen S, Chaparro M, Allocca M, Arnott I, Bossuyt P, Burisch J, Campmans-Kuijpers M, de Ridder L, Dignass A, Drohan C, Feakins R, Gilardi D, Grosek J, Gross E, Hart A, Jaghult S, Katsanos K,

Lonnfors S, Panis Y, Perovic M, Pierik M, Rimola J, Tulchinsky H,Gisbert JP. Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. **Journal of Crohn's & colitis** *2020;14(8):1037-1048*

65) **Fiorino G**, Colombo M, Natale C, Azzolini E, Lagioia M,Danese S. Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. **Annals of internal medicine** *2020;173(5):405-407*

66) D'Amico F, **Fiorino G**, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L,Danese S. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. **Expert review of gastroenterology & hepatology** *2020;14(9):765-773*

67) Zacharopoulou E, Craviotto V, **Fiorino G**, Furfaro F, Zilli A, Gilardi D, Peyrin-Biroulet L, Danese S,Allocca M. Targeting the gut layers in Crohn's disease: mucosal or transmural healing? **Expert review of gastroenterology & hepatology** *2020;14(9):775-787*

68) Zilli A, Capogreco A, Furfaro F, Allocca M, Roda G, Loy L, **Fiorino G**,Danese S. Improving quality of care in endoscopy of inflammatory bowel disease: can we do better? **Expert review of gastroenterology & hepatology** *2020;14(9):819-828*

69) Gilardi D, Gabbiadini R, Allocca M, Correale C, **Fiorino G**, Furfaro F, Zilli A, Peyrin-Biroulet L,Danese S. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. **Expert review of gastroenterology & hepatology** *2020;14(9):797-806*

70) Vespa E, Furfaro F, Allocca M, **Fiorino G**, Correale C, Gilardi D, Argollo M, Zilli A, Zacharopoulou E, Loy L,Danese S. Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. **Expert review of gastroenterology & hepatology** *2020;14(9):829-841*

71) Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D'Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris GJ, Papaconstantinou I, Katsanos K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert JP, Danese S,**Fiorino G**. Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. **Journal of clinical medicine** *2020;9(11):*

72) Fantini MC, Biancone L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Guglielmi FW, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Di Ruscio M, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Saibeni S,**Fiorino G**. Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. **Inflamm Bowel Dis** *2020;26(11):e134-e136*

73) Allocca M, Guidelli GM, Borroni RG, Selmi C, Narcisi A, Danese S,**Fiorino G**. Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. **Pharmacological research** *2020;160(105061*

74) **Fiorino G**, Gilardi D, Radice S, Furfaro F, Allocca M,Danese S. Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. **The American journal of gastroenterology** *2020;115(10):1719-1721*

75) Solitano V, D'Amico F, **Fiorino G**, Peyrin-Biroulet L,Danese S. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. **Expert Rev Clin Immunol** *2020;16(10):1019-1028*

76) Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, Ghalim F, Carbonnel F, Verstockt B, Festa S, Maia L, Berrozpe A, Zagorowicz E, Savarino E, Ellul P, Vavricka SR, Calvo M, Koutroubakis I, Hoentjen F, Salazar LF, Callela F, Canete Pizarro F, Soufleris K, Sonnenberg E, Cavicchi M, Wypych J, Hommel C, Ghiani A, **Fiorino G**,Ecco Confer C. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. **Journal of Crohn's & colitis** *2020;14(4):480-489*

77) Danese S, **Fiorino G**,Peyrin-Biroulet L. Positioning Therapies in Ulcerative Colitis. **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2020;18(6):1280-1290 e1*

78) **Fiorino G**, Bonifacio C, Allocca M,Danese S. Impact of therapies on bowel damage in Crohn's disease. **United European gastroenterology journal** *2020;8(4):410-417*

79) Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A, Ribaldone DG, Buda A, Bezzio C, **Fiorino G**, Fantini MC, Scaldaferri F, Guidi L, Danese S, Gasbarrini A, Orlando A,Armuzzi A. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. **Journal of Crohn's & colitis** *2020;*Epub ahead of print

80) Allocca M, **Fiorino G**, Furfaro F, Gilardi D, Radice S, D'Amico F, Zilli A,Danese S. Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2020;18(8):1882-1883*

81) Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Vigano C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini MC, Armuzzi A, Daperno M, **Fiorino G**,Italian Group for the Study of Inflammatory Bowel D. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. **Gut** *2020;69(7):1213-1217*

82) **Fiorino G**, Peyrin-Biroulet L,Danese S. Protecting patients with IBD during the COVID-19 pandemic. **The lancet. Gastroenterology & hepatology** *2020;5(7):639*

83) Gadaleta RM, Garcia-Irigoyen O, Cariello M, Scialpi N, Peres C, Vetrano S, **Fiorino G**, Danese S, Ko B, Luo J, Porru E, Roda A, Sabba C,Moschetta A. Corrigendum to 'Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor': [EBioMedicine 54 (2020) 102719]. **EBioMedicine** *2020;57(102873*

84) Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, Gonzalez-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O,**Fiorino G**. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. **Journal of Crohn's & colitis** *2020;14(1):4-22*

85) Lenti MV, Armuzzi A, Castiglione F, Fantini MC, **Fiorino G**, Orlando A, Pugliese D, Rizzello F, Vecchi M, Di Sabatino A,Ig IBD. Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. **Digestive and liver disease : official journal of the Italian Society of**

Gastroenterology and the Italian Association for the Study of the Liver *2020;52(1):44-50*

86) Lenti MV, Armuzzi A, Castiglione F, Fantini MC, **Fiorino G**, Orlando A, Pugliese D, Rizzello F, Vecchi M, Di Sabatino A,IG-IBD obot. Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2020;52(1):44-50*

87) Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, Doherty G, El-Hussuna A, Ellul P, **Fiorino G**, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Gomollon F, Gonzalez Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B,Zmora O. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. **Journal of Crohn's & colitis** *2020;14(2):155-168*

88) D'Amico F, Pouillon L, Argollo M, Hart A, **Fiorino G**, Vegni E, Radice S, Gilardi D, Fazio M, Leone S, Bonovas S, Magro F, Danese S,Peyrin-Biroulet L. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2020;52(2):138-142*

89) **Fiorino G**, Bonovas S, Gilardi D, Di Sabatino A, Allocca M, Furfaro F, Roda G, Lenti MV, Aronico N, Mengoli C, Angeli E, Gaffuri N, Peyrin-Biroulet L,Danese S. Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners. **Journal of Crohn's & colitis** *2020;14(12):1777-1779*

90) Carvello M, Di Candido F, Greco M, Foppa C, Maroli A, **Fiorino G**, Cecconi M, Danese S,Spinelli A. The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease. **Updates in surgery** *2020;72(4):985-989*

91) Saibeni S, Scucchi L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Mazzuoli S, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Ruscio MD, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Fantini MC, **Fiorino G**,Ig IBD. Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. **United European gastroenterology journal** *2020;8(10):1228-1235*

92) D'Amico F, Peyrin-Biroulet L, Danese S,**Fiorino G**. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? **Current opinion in pharmacology** *2020;55(141-150*

93) Allocca M, **Fiorino G**, Zallot C, Furfaro F, Gilardi D, Radice S, Danese S,Peyrin-Biroulet L. Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2020;18(9):2134-2135*

94) Furfaro F, Vuitton L, **Fiorino G**, Koch S, Allocca M, Gilardi D, Zilli A, D'Amico F, Radice S, Chevaux JB, Schaefer M, Chaussade S, Danese S,Peyrin-Biroulet L. SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. **Nat Rev Gastroenterol Hepatol** *2020;17(8):507-516*

95) **Fiorino G**, Allocca M, Correale C, Roda G, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L,Danese S. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. **Expert Opin Biol Ther** *2020;20(4):421-427*

96) Gadaleta RM, Garcia-Irigoyen O, Cariello M, Scialpi N, Peres C, Vetrano S, **Fiorino G**, Danese S, Ko B, Luo J, Porru E, Roda A, Sabba C,Moschetta A. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. **EBioMedicine** *2020;54(102719*

97) Sammarco G, Shalaby M, Elangovan S, Petti L, Roda G, Restelli S, Arena V, Ungaro F, **Fiorino G**, Day AJ, D'Alessio S,Vetrano S. Hyaluronan Accelerates Intestinal Mucosal Healing through Interaction with TSG-6. **Cells** *2019;8(9):*

98) Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, Ghalim F, Carbonnel F, Verstockt B, Festa S, Maia L, Berrozpe A, Zagorowicz E, Savarino E, Ellul P, Vavricka SR, Calvo M, Koutroubakis I, Hoentjen F, Luis FS, Callela F, Canete Pizarro F, Soufleris K, Sonnenberg E, Cavicchi M, Wypych J, Hommel C, Ghiani A,**Fiorino G**. Interstitial and Granulomatous lung disease in inflammatory bowel disease patients. **Journal of Crohn's & colitis** *2019;14(4):480-489*

99) **Fiorino G**, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L,Danese S. Biosimilars of adalimumab: the upcoming challenge in IBD. **Expert Opin Biol Ther** *2019;19(10):1023-1030*

100) Allocca M, **Fiorino G**, Bonifacio C, Peyrin-Biroulet L,Danese S. Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2019;17(12):2397-2415*

101) Viola A, Monterubbianesi R, Scalisi G, Furfaro F, Rea M, Saibeni S, Aratari A, Bringiotti R, Casella G, Cantoro L, Frankovic I, Calella F, Pugliese D, Orlando S, Samperi L, Cappello M, Mocci G, Manetti N, Annese V, Privitera AC, Inserra G, Caprioli F, D'Inca R, Principi M, Papi C, Castiglione F, Danese S, Ardizzone S, Bossa F, Kohn A, Manguso F, Alibrandi A, **Fiorino G**, Armuzzi A, Fries W,Italian Group for the Study of Inflammatory Bowel D. Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. **European journal of gastroenterology & hepatology** *2019;31(11):1361-1369*

102) **Fiorino G**, Sturniolo GC, Bossa F, Cassinotti A, di Sabatino A, Giuffrida P,Danese S. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. **Cells** *2019;8(6):*

103) Ellul P, Zammit SC, Katsanos KH, Cesarini M, Allocca M, Danese S, Karatzas P, Moreno SC, Kopylov U, **Fiorino G**, Torres J, Lopez-Sanroman A, Caruana M, Zammit L,Mantzaris G. Corrigendum: Perception of Reproductive Health in Women with Inflammatory Bowel Disease. **Journal of Crohn's & colitis** *2019;13(6):815*

104) D'Amico F, **Fiorino G**, Peyrin-Biroulet L,Danese S. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. **Immunotherapy** *2019;11(7):565-575*

105) **Fiorino G**, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A,National patients' association r. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). **Digestive and liver disease : official**

journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver *2019;51(5):632-639*

106) Pouillon L, Danese S, Hart A, **Fiorino G**, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, Gonzalez-Lorenzo M, Bonovas S, Magro F,Peyrin-Biroulet L. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. **Aliment Pharmacol Ther** *2019;49(9):1181-1187*

107) **Fiorino G**, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F,Armuzzi A. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2019;51(5):632-639*

108) D'Haens GR, Cabrijan Z, Eberhardson M, van den Berg RM, Lowenberg M, Danese S, **Fiorino G**, Levine YA,Chernoff DN. VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY AND MODULATES SERUM AND AUTONOMIC BIOMARKERS IN BIOLOGICREFRACTORY CROHN'S DISEASE. **Gastroenterology** *2019;156(6):S75-S75*

109) Danese S, Hart A, Dignass A, **Fiorino G**, Louis E, D'Haens GR, Dotan I, Rogler G, Paridaens K,Peyrin-Biroulet L. A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY ASSESSING THE EFFECTIVENESS OF BUDESONIDE MMX (R) FOR MILD-TO-MODERATE ULCERATIVE COLITIS. **Gastroenterology** *2019;156(6):S1129-S1129*

110) Vegni E, Gilardi D, Bonovas S, Corro BE, Menichetti J, Leone D, Mariangela A, Furfaro F, Danese S,**Fiorino G**. Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. **Journal of Crohn's & colitis** *2019;13(4):417-423*

111) Sturm A, Maaser C, Calabrese E, Annese V, **Fiorino G**, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustins E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, Gonzalez Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J, European Cs, Colitis O, the European Society of G,Abdominal R. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. **Journal of Crohn's & colitis** *2019;13(3):273-284*

112) Loy L, Roda G, **Fiorino G**, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L,Danese S. Detection and management of early stage inflammatory bowel disease: an update for clinicians. **Expert review of gastroenterology & hepatology** *2019;13(6):547-555*

113) **Fiorino G**, Peyrin-Biroulet L,Danese S. Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. **Gastroenterology** *2019;156(8):2349-2351*

114) Leone D, Gilardi D, Corro BE, Menichetti J, Vegni E, Correale C, Mariangela A, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S,**Fiorino G**. Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. **Inflamm Bowel Dis** *2019;25(8):1399-1407*

115) Pugliese D, Daperno M, **Fiorino G**, Savarino E, Mosso E, Biancone L, Testa A, Sarpi L, Cappello M, Bodini G, Caprioli F, Festa S, Laino G, Maconi G, Mazzuoli S, Mocci G, Sartini A, D'Amore A, Alivernini S, Gremese E,Armuzzi A. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. **Digestive and**

liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver *2019;51(7):972-977*

116) **Fiorino G**, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L,Gisbert JP. 'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. **Journal of Crohn's & colitis** *2019;13(1):127-137*

117) Armuzzi A, **Fiorino G**, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D'Inca R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V,Investigators P. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. **Inflamm Bowel Dis** *2019;25(3):568-579*

118) Beeg M, Nobili A, Orsini B, Rogai F, Gilardi D, **Fiorino G**, Danese S, Salmona M, Garattini S,Gobbi M. A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. **Sci Rep** *2019;9(1):2064*

119) Maaser C, Sturm A, Vavricka SR, Kucharzik T, **Fiorino G**, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, Gonzalez-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustins E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J, European Cs, Colitis O, the European Society of G,Abdominal R. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. **Journal of Crohn's & colitis** *2019;13(2):144-164*

120) Iacucci M, Cannatelli R, Tontini GE, Panaccione R, Danese S, **Fiorino G**, Matsumoto T, Kochhar GS, Shen B, Kiesslich R,Ghosh S. Improving the quality of surveillance colonoscopy in inflammatory bowel disease. **The lancet. Gastroenterology & hepatology** *2019;4(12):971-983*

121) Limdi JK, Lobo A, Finnegan A, Hayee B, Peyrin-Biroulet L, Sturm A, **Fiorino G**, Burisch J, Terry H, Avedano L, Tucknott S, Rose A, Sebastian S, Noone D,Evans J. The Socioeconomic Impact of Living with Ulcerative Colitis, a Burden of Illness Study. **J. Gastroenterol. Hepatol.** *2019;34(786-786*

122) Limdi J, Lobo A, Finnegan A, Hayee B, Peyrin-Biroulet L, Sturm A, **Fiorino G**, Burisch J, Terry H, Avedano L, Tucknott S, Rose A, Sebastian S, Noone D,Evans J. The Impact of Ulcerative Colitis on Quality of Life and Productivity across Europe, a Burden of Illness Study. **J. Gastroenterol. Hepatol.** *2019;34(208-208*

123) Leone D, Gilardi D, Corro BE, Menichetti J, Vegni E, Correale C, Allocca M, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S,**Fiorino G**. Psychological Functioning of Patients With Inflammatory Bowel Disease. **Inflamm Bowel Dis** *2019;25(9):e112*

124) Roda G, Porru E, Katsanos K, Skamnelos A, Kyriakidi K, **Fiorino G**, Christodoulou D, Danese S,Roda A. Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. **Cells** *2019;8(8):*

125) Viola A, Pugliese D, Renna S, Furfaro F, Caprioli F, D'Inca R, Bossa F, Mazza S, Costantino G, Fantini MC, **Fiorino G**, Alibrandi A, Orlando A, Armuzzi A,Fries W. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2019;51(4):510-515*

126) Danese S,**Fiorino G**. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. **Curr Med Chem** *2019;26(2):280-287*

127) Argollo M, Gilardi D, Roda G, **Fiorino G**, Peyrin-Biroulet L,Danese S. Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time? **Current pharmaceutical design** *2019;25(1):47-56*

128) Argollo M, **Fiorino G**, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L,Danese S. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? **Current pharmaceutical design** *2019;25(1):7-12*

129) D'Amico F, Parigi TL, **Fiorino G**, Peyrin-Biroulet L,Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. **Therapeutic advances in gastroenterology** *2019;12(1756284819848631*

130) Candido FD, **Fiorino G**, Spadaccini M, Danese S,Spinelli A. Are Surgical Rates Decreasing in the Biological Era In IBD? **Curr Drug Targets** *2019;20(13):1356-1362*

131) Goncalves J, Santos M, Acurcio R, Iria I, Gouveia L, Matos Brito P, Catarina Cunha-Santos A, Barbas A, Galvao J, Barbosa I, Aires da Silva F, Alcobia A, Cavaco M, Cardoso M, Delgado Alves J, Carey JJ, Dorner T, Eurico Fonseca J, Palmela C, Torres J, Lima Vieira C, Trabuco D, **Fiorino G**, Strik A, Yavzori M, Rosa I, Correia L, Magro F, D'Haens G, Ben-Horin S, Lakatos PL,Danese S. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. **Aliment Pharmacol Ther** *2018;48(5):507-522*

132) Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, **Fiorino G**, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I,Ferrante M. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. **Inflamm Bowel Dis** *2018;24(11):2442-2451*

133) Allocca M, **Fiorino G**, Bonovas S, Furfaro F, Gilardi D, Argollo M, Magnoni P, Peyrin-Biroulet L,Danese S. Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. **Journal of Crohn's & colitis** *2018;12(12):1385-1391*

134) Allocca M, **Fiorino G**, Bonifacio C, Furfaro F, Gilardi D, Argollo M, Peyrin-Biroulet L,Danese S. Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. **Journal of Crohn's & colitis** *2018;12(11):1280-1287*

135) Sebastian S, Black C, Pugliese D, Armuzzi A, Sahnan K, Elkady SM, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fearnhead NS, Kopylov U, Davidov Y, Bosca-Watts MM, Ellul P, Muscat M, Karmiris K, Hart AL, Danese S, Ben-Horin S,**Fiorino G**. The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. **Aliment Pharmacol Ther** *2018;48(9):941-950*

136) D'Haens GR, Cabrijan Z, Eberhardson M, van den Berg RM, Lowenberg M, **Fiorino G**, Danese S, Levine YA,Chernoff D. THE EFFECTS OF VAGUS NERVE STIMULATION IN BIOLOGIC-REFRACTORY CROHN'S DISEASE: A PROSPECTIVE CLINICAL TRIAL. **Gastroenterology** *2018;154(6):S847-S847*

137) Allocca M, **Fiorino G**, Furfaro F, Radice S, Gilardi D, Peyrin-Biroulet L,Danese S. BOWEL ULTRASOUND IS ACCURATE IN ASSESSING DISEASE

ACTIVITY IN ULCERATIVE COLITIS. **Gastroenterology** *2018;154(6):S391-S392*

138) Allocca M, Gilardi D, **Fiorino G**, Furfaro F, Peyrin-Biroulet L,Danese S. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. **European journal of gastroenterology & hepatology** *2018;30(3):316-322*

139) Argollo M, **Fiorino G**, Peyrin-Biroulet L,Danese S. Vedolizumab for the treatment of Crohn's disease. **Expert Rev Clin Immunol** *2018;14(3):179-189*

140) Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Biron AI, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Shitrit BA, Gutierrez A, Doherty GA, Fernandez-Salazar L, Cadilla MJ, Huguet JM, O'Toole A, Stasi E, Marcos MN, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Palomares DM, **Fiorino G**, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Bradley FI, Roman LA, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, de Carpi MFJ,Gisbert JP. Long-Term Safety of In Utero Exposure to Anti-TNFalpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. **The American journal of gastroenterology** *2018;113(3):396-403*

141) Viola A, Pugliese D, Renna S, Furfaro F, Caprioli F, D'Inca R, Bossa F, Costantino G, Fantini MC, **Fiorino G**, Armuzzi A, Orlando A,Fries W. OUTCOME IN ULCERATIVE COLITIS AFTER SWITCH FROM SUBCUTANEOUS ANTI-TNF TO INTRAVENOUS ANTI-TNF: A MULTICENTRE STUDY. **Dig. Liver Dis.** *2018;50(2):E193-E193*

142) Danese S, Bonovas S, Lopez A, **Fiorino G**, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G,Peyrin-Biroulet L. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. **Gastroenterology** *2018;155(1):76-87*

143) D'Amico F, **Fiorino G**, Furfaro F, Allocca M,Danese S. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. **Expert opinion on investigational drugs** *2018;27(7):595-599*

144) Allocca M, Gilardi D, **Fiorino G**, Furfaro F, Argollo M, Peyrin-Biroulet L,Danese S. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. **Expert opinion on investigational drugs** *2018;27(7):623-629*

145) **Fiorino G**, D'Amico F, Italia A, Gilardi D, Furfaro F,Danese S. JAK inhibitors: Novel developments in management of ulcerative colitis. **Best practice & research. Clinical gastroenterology** *2018;32-33(89-93*

146) Allocca M, Furfaro F, **Fiorino G**, Gilardi D, D'Alessio S,Danese S. Can IL-23 be a good target for ulcerative colitis? **Best practice & research. Clinical gastroenterology** *2018;32-33(95-102*

147) **Fiorino G**, Ruiz-Arguello MB, Maguregui A, Nagore D, Correale C, Radice S, Gilardi D, Allocca M, Furfaro F, Martinez A,Danese S. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. **Inflamm Bowel Dis** *2018;24(3):601-606*

148) Bonovas S, Nikolopoulos GK, Lytras T, **Fiorino G**, Peyrin-Biroulet L,Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. **British journal of clinical pharmacology** *2018;84(2):239-251*

149) Allocca M, **Fiorino G**, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L,Danese S. Biologic Therapies in Ulcerative Colitis: Primi Inter Pares? **Curr Drug Targets** *2018;19(7):748-756*

150) Menichetti J, **Fiorino G**,Vegni E. Personalizing Psychological Treatment Along the IBD Journey: From Diagnosis to Surgery. **Curr Drug Targets** *2018;19(7):722-728*

151) Allocca M, **Fiorino G**,Danese S. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? **Digestive diseases and sciences** *2017;62(11):2964-2965*

152) Ungaro F, Tacconi C, Massimino L, Corsetto PA, Correale C, Fonteyne P, Piontini A, Garzarelli V, Calcaterra F, Della Bella S, Spinelli A, Carvello M, Rizzo AM, Vetrano S, Petti L, **Fiorino G**, Furfaro F, Mavilio D, Maddipati KR, Malesci A, Peyrin-Biroulet L, D'Alessio S,Danese S. MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. **Gastroenterology** *2017;153(5):1363-1377 e6*

153) **Fiorino G**, Correale C, Radice S, Allocca M, Furfaro F, Gilardi D, Nagore D, Del Rio L, Pascual J, Martinez A,Danese S. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. **Aliment Pharmacol Ther** *2017;46(9):903-905*

154) Furfaro F, Gilardi D, Allocca M, Cicerone C, Correale C, **Fiorino G**,Danese S. IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy. **Expert Rev Clin Immunol** *2017;13(5):457-467*

155) Bonovas S, **Fiorino G**, Lytras T, Nikolopoulos G, Peyrin-Biroulet L,Danese S. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. **Aliment Pharmacol Ther** *2017;45(9):1179-1192*

156) **Fiorino G**, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, Laurent V, Zallot C, Peyrin-Biroulet L,Danese S. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. **Journal of Crohn's & colitis** *2017;11(3):274-280*

157) Bonovas S, **Fiorino G**, Lytras T, Nikolopoulos G, Peyrin-Biroulet L,Danese S. Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply. **Aliment Pharmacol Ther** *2017;45(12):1554-1555*

158) Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, **Fiorino G**, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P,Ecco. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. **Journal of Crohn's & colitis** *2017;11(1):3-25*

159) Fries W, Viola A, Manetti N, Frankovic I, Pugliese D, Monterubbianesi R, Scalisi G, Aratari A, Cantoro L, Cappello M, Samperi L, Saibeni S, Casella G, Mocci G, Rea M, Furfaro F, Contaldo A, Magarotto A, Calella F, Manguso F, Inserra G, Privitera AC, Principi M, Castiglione F, Caprioli F, Ardizzone S, Danese S, Papi C, Bossa F, Kohn A, Armuzzi A, D'Inca R, Annese V, Alibrandi A, Bonovas S, **Fiorino G**,Italian Group for the study of Inflammatory Bowel D. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2017;49(1):17-23*

160) Danese S, **Fiorino G**, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J,Peyrin-Biroulet L. ECCO Position

Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. **Journal of Crohn's & colitis** *2017;11(1):26-34*

161) Katsanos KH, Domenech E, Rahier JF, Kopylov U, **Fiorino G**, Rogler G, Louis E,Ben-Horin S. Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. **Journal of Crohn's & colitis** *2017;11(2):256-257*

162) **Fiorino G**, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, D'Inca R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V,Cohort P-B. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. **Inflamm Bowel Dis** *2017;23(2):233-243*

163) Sigall-Boneh R, Levine A, Lomer M, Wierdsma N, Allan P, **Fiorino G**, Gatti S, Jonkers D, Kierkus J, Katsanos KH, Melgar S, Yuksel ES, Whelan K, Wine E,Gerasimidis K. Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. **Journal of Crohn's & colitis** *2017;11(12):1407-1419*

164) Argollo M, **Fiorino G**, Hindryckx P, Peyrin-Biroulet L,Danese S. Novel therapeutic targets for inflammatory bowel disease. **Journal of autoimmunity** *2017;85(103-116*

165) Danese S, **Fiorino G**,Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials. **Gut** *2017;66(12):2179-2187*

166) Gilardi D, **Fiorino G**, Furfaro F, Alfieri MF, Orlandi I, Allocca M,Danese S. Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. **Minerva gastroenterologica e dietologica** *2017;63(4):319-326*

167) Allocca M, Bonifacio C, **Fiorino G**, Spinelli A, Furfaro F, Balzarini L, Bonovas S,Danese S. Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2017;49(8):872-877*

168) Danese S, **Fiorino G**,Peyrin-Biroulet L. Filgotinib in Crohn's Disease: JAK Is Back. **Gastroenterology** *2017;153(2):603-605*

169) **Fiorino G**, Bonovas S, Cicerone C, Allocca M, Furfaro F, Correale C,Danese S. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. **Expert opinion on drug safety** *2017;16(4):437-443*

170) Allocca M, Landi R, Bonovas S, **Fiorino G**, Papa A, Spinelli A, Furfaro F, Peyrin-Biroulet L, Armuzzi A,Danese S. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. **Digestion** *2017;96(3):166-172*

171) Avila-Ribeiro P, **Fiorino G**,Danese S. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. **Current pharmaceutical design** *2017;23(44):6759-6769*

172) Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, **Fiorino G**, Travis S, Mary JY,Peyrin-Biroulet L. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. **Gut** *2016;65(9):1447-55*

173) Bonovas S, **Fiorino G**, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L,Danese S. Biologic Therapies and Risk of Infection and Malignancy

in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2016;14(10):1385-1397 e10*

174) **Fiorino G**, Cortes PN, Ellul P, Felice C, Karatzas P, Silva M, Lakatos PL, Bossa F, Ungar B, Sebastian S, Furfaro F, Karmiris K, Katsanos KH, Muscat M, Christodoulou DK, Maconi G, Kopylov U, Magro F, Mantzaris GJ, Armuzzi A, Bosca-Watts MM, Ben-Horin S, Bonovas S,Danese S. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2016;14(10):1426-1432 e1*

175) **Fiorino G**,Danese S. Diagnostic Delay in Crohn's Disease: Time for Red Flags. **Digestive diseases and sciences** *2016;61(11):3097-3098*

176) Danese S, **Fiorino G**,Michetti P. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. **Journal of Crohn's & colitis** *2016;10(11):1362-1365*

177) **Fiorino G**,Danese S. Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? **Journal of Crohn's & colitis** *2016;10(11):1257-1258*

178) Bonovas S, **Fiorino G**, Lytras T, Malesci A,Danese S. Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. **World J Gastroenterol** *2016;22(18):4594-603*

179) Furfaro F, **Fiorino G**, Allocca M, Gilardi D,Danese S. Emerging therapeutic targets and strategies in Crohn's disease. **Expert review of gastroenterology & hepatology** *2016;10(6):735-44*

180) Kopylov U, Katsanos KH, van der Woude CJ, Karmiris K, Hernandez V, Odes S, Papamichael K, Koutroubakis IE, Bojic D, Kaimakliotis I, **Fiorino G**, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris GJ, Jojic N, Paspatis G, Christodoulou DK, Ben-Horin S,Tsianos EV. European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. **European journal of gastroenterology & hepatology** *2016;28(7):802-6*

181) **Fiorino G**, Gilardi D,Danese S. The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. **Therapeutic advances in gastroenterology** *2016;9(4):503-12*

182) Bonovas S, **Fiorino G**, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L,Danese S. Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **Medicine** *2016;95(2):e2308*

183) Lopez-Posadas R, Becker C, Gunther C, Tenzer S, Amann K, Billmeier U, Atreya R, **Fiorino G**, Vetrano S, Danese S, Ekici AB, Wirtz S, Thonn V, Watson AJ, Brakebusch C, Bergo M, Neurath MF,Atreya I. Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. **The Journal of clinical investigation** *2016;126(2):611-26*

184) Ellul P, Zammita SC, Katsanos KH, Cesarini M, Allocca M, Danese S, Karatzas P, Moreno SC, Kopylov U, **Fiorino G**, Torres J, Lopez-Sanroman A, Caruana M, Zammit L,Mantzaris G. Perception of Reproductive Health in Women with Inflammatory Bowel Disease. **Journal of Crohn's & colitis** *2016;10(8):886-91*

185) **Fiorino G**, Bonifacio C, Peyrin-Biroulet L,Danese S. Preventing Collateral Damage in Crohn's Disease: The Lemann Index. **Journal of Crohn's & colitis** *2016;10(4):495-500*

186) **Fiorino G**, Fazio M,Danese S. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile? **Expert Rev Clin Immunol** *2016;12(4):361-3*

187) Danese S, Peyrin-Biroulet L,**Fiorino G**. Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball? **Gut** *2015;64(9):1347-8*

188) **Fiorino G**,Omodei PD. Psoriasis and Inflammatory Bowel Disease: Two Sides of the Same Coin? **Journal of Crohn's & colitis** *2015;9(9):697-8*

189) Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, **Fiorino G**, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Jr., Marteau P, Munkholm P, Murdoch TB, Ordas I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S,Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. **The American journal of gastroenterology** *2015;110(9):1324-38*

190) **Fiorino G**, Allocca M,Danese S. Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? **Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association** *2015;13(10):1767-9*

191) Danese S, **Fiorino G**,Peyrin-Biroulet L. Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way? **Gastroenterology** *2015;149(4):1121-3*

192) Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, **Fiorino G**, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E,Eliakim R. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. **Journal of Crohn's & colitis** *2015;9(11):945-65*

193) Gilardi D, **Fiorino G**, Allocca M, Bravata I,Danese S. Golimumab: clinical update on its use for ulcerative colitis. **Drugs of today** *2015;51(3):171-84*

194) Moja L, Danese S, **Fiorino G**, Del Giovane C,Bonovas S. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. **Aliment Pharmacol Ther** *2015;41(11):1055-65*

195) Quetglas EG, Armuzzi A, Wigge S, **Fiorino G**, Barnscheid L, Froelich M,Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. **European journal of clinical pharmacology** *2015;71(7):773-99*

196) Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV, Jr., Louis E, Panes J, Scholmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, **Fiorino G**, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel JF,Cosnes J. Development of the Lemann index to assess digestive tract damage in patients with Crohn's disease. **Gastroenterology** *2015;148(1):52-63 e3*

197) Bravata I, **Fiorino G**, Allocca M, Repici A,Danese S. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus

kinases are looking toward a more effective treatment of inflammatory bowel disease. **Scandinavian journal of gastroenterology** *2015;50(1):113-20*

198) van der Woude CJ, Ardizzone S, Bengtson MB, **Fiorino G**, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N, Selinger C, Sebastian S, Sturm A, Zelinkova Z, Magro F, European Cs,Colitis O. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. **Journal of Crohn's & colitis** *2015;9(2):107-24*

199) van der Woude CJ, Ardizzone S, Bengtson MB, **Fiorino G**, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N, Selinger C, Sebastian S, Sturm A, Zelinkova Z,Magro F. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. **Journal of Crohn's & colitis** *2015;9(2):107-24*

200) Bravata I, Allocca M, **Fiorino G**,Danese S. Integrins and adhesion molecules as targets to treat inflammatory bowel disease. **Current opinion in pharmacology** *2015;25(67-71*

201) Danese S, **Fiorino G**, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L,Colombel JF. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. **Journal of Crohn's & colitis** *2015;9(8):601-6*

202) **Fiorino G**, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L,Danese S. Bowel Damage as Assessed by the Lemann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. **Journal of Crohn's & colitis** *2015;9(8):633-9*

203) Fernandes C, Allocca M, Danese S,**Fiorino G**. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. **Immunotherapy** *2015;7(2):175-90*

204) Nuti F, **Fiorino G**,Danese S. Adalimumab for the treatment of pediatric Crohn's disease. **Expert Rev Clin Immunol** *2015;11(9):963-72*

205) Gilardi D, **Fiorino G**, Genua M, Allocca M,Danese S. Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? **Expert review of gastroenterology & hepatology** *2014;8(7):835-46*

206) Danese S, **Fiorino G**,Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. **Journal of Crohn's & colitis** *2014;8(11):1548-50*

207) Lazzaro C, Cappello M, Cortelezzi C, Costantino G, **Fiorino G**, Mastronardi M, Giannotta M, Galletti B, Cicala M, Vadala di Prampero S, Gualberti G, Caprioli F, Gasbarrini A,Fattore G. A Health Technology-Related Cost Description Concerning Italian Ibd Centres Dealing With Crohn's Disease Results From Sole Study. **Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research** *2014;17(7):A370*

208) Lazzaro C, Cappello M, Cortelezzi C, Costantino G, **Fiorino G**, Mastronardi M, Giannotta M, Galletti B, Cicala M, Vadala di Prampero S, Gualberti G, Caprioli F, Gasbarrini A,Meregaglia M. Health-Related Quality of Life in Italian Patients With Moderate and Severe Crohn's Disease: Interim Results from the Sole Study. **Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research** *2014;17(7):A570-1*

209) Danese S, **Fiorino G**, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L,Bonovas S. Biological agents for moderately to severely active ulcerative

colitis: a systematic review and network meta-analysis. **Annals of internal medicine** *2014;160(10):704-11*

210) **Fiorino G**,Danese S. Commentary: Adjunct antibiotic combination therapy for ulcerative colitis--is it time to investigate Fusobacterium varium? **Aliment Pharmacol Ther** *2014;39(11):1333*

211) **Fiorino G**,Danese S. The biosimilar road in inflammatory bowel disease: the right way? **Best practice & research. Clinical gastroenterology** *2014;28(3):465-71*

212) Allocca M, **Fiorino G**, Vermeire S, Reinisch W, Cataldi F,Danese S. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. **Expert Rev Clin Immunol** *2014;10(7):885-95*

213) **Fiorino G**, Girolomoni G, Lapadula G, Orlando A, Danese S,Olivieri I. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. **Autoimmunity reviews** *2014;13(7):751-5*

214) **Fiorino G**, Danese S, Pariente B,Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. **Autoimmunity reviews** *2014;13(1):15-9*

215) Spinelli A, **Fiorino G**, Bazzi P, Sacchi M, Bonifacio C, De Bastiani S, Malesci A, Balzarini L, Peyrin-Biroulet L, Montorsi M,Danese S. Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. **Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract** *2014;18(1):83-90; discussion 90-1*

216) **Fiorino G**, Allocca M,Danese S. Commentary: anaemia in inflammatory bowel disease--the most common and ignored extra intestinal manifestation. **Aliment Pharmacol Ther** *2014;39(2):227-8*

217) Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S, Danese S,**Fiorino G**. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2014;46(2):135-9*

218) **Fiorino G**,Danese S. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa. **Gastroenterology** *2014;147(6):1433-5*

219) Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, **Fiorino G**, Nardone OM, De Vitis I, Papa A, Rapaccini GL,Guidi L. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. **Inflamm Bowel Dis** *2014;20(8):1368-74*

220) **Fiorino G**, Gilardi D, Naccarato P, Sociale OR,Danese S. Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. **Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver** *2014;46(4):330-4*

221) Leone D, Menichetti J, **Fiorino G**,Vegni E. State of the art: psychotherapeutic interventions targeting the psychological factors involved in IBD. **Curr Drug Targets** *2014;15(11):1020-9*

222) Danese S, **Fiorino G**, Fernandes C,Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn's disease. **Curr Drug Targets** *2014;15(11):1056-63*

223) Allocca M, **Fiorino G**,Danese S. Iron deficiency: the hidden miscreant in inflammatory bowel disease. **Curr Drug Targets** *2014;15(11):1011-9*

224) Allocca M, **Fiorino G**,Danese S. Commentary: antibodies reacting with the infliximab Fab portion--something new? **Aliment Pharmacol Ther** *2013;38(5):552*

225) Jovani M, **Fiorino G**,Danese S. Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. **Curr Drug Targets** *2013;14(12):1444-52*

226) **Fiorino G**, Bonifacio C, Padrenostro M, Sposta FM, Spinelli A, Malesci A, Balzarini L, Peyrin-Biroulet L,Danese S. Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease. **Digestive diseases and sciences** *2013;58(11):3246-55*

227) Allocca M, Jovani M, **Fiorino G**, Schreiber S,Danese S. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. **Curr Drug Targets** *2013;14(12):1508-21*

228) Cammarota T, Ribaldone DG, Resegotti A, Repici A, Danese S, **Fiorino G**, Sarno A, Robotti D, Debani P, Bonenti G, Pellicano R, Andrealli A, Sapone N, Simondi D, Bresso F,Astegiano M. Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. **Scandinavian journal of gastroenterology** *2013;48(5):552-5*

229) Peyrin-Biroulet L, **Fiorino G**, Buisson A,Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? **Nat Rev Gastroenterol Hepatol** *2013;10(6):345-51*

230) Spinelli A, Bazzi P, Sacchi M, Danese S, **Fiorino G**, Malesci A, Gentilini L, Poggioli G,Montorsi M. Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis. **Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract** *2013;17(1):126-32; discussion p 132*

231) Jovani M, **Fiorino G**,Danese S. Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome. **Aliment Pharmacol Ther** *2013;37(2):277-8*

232) Iborra M, Bernuzzi F, Correale C, Vetrano S, **Fiorino G**, Beltran B, Marabita F, Locati M, Spinelli A, Nos P, Invernizzi P,Danese S. Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. **Clinical and experimental immunology** *2013;173(2):250-8*

233) Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, **Fiorino G**, Sociale O, Papa A, De Vitis I, Rapaccini GL,Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. **Inflamm Bowel Dis** *2013;19(5):1065-72*

234) Indriolo A, Fagiuoli S, Pasulo L, **Fiorino G**, Danese S,Ravelli P. Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation. **Aliment Pharmacol Ther** *2013;37(8):840-2*

235) Cesarini M,**Fiorino G**. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update. **Expert Rev Clin Immunol** *2013;9(4):301-6*

236) Allocca M, **Fiorino G**,Danese S. Cross-sectional imaging modalities in Crohn's disease. **Digestive diseases** *2013;31(2):199-201*

237) Chevaux JB, **Fiorino G**, Frederic M,Peyrin-Biroulet L. Capsule endoscopy in Crohn's disease. **Curr Drug Targets** *2012;13(10):1261-7*

238) **Fiorino G**, Cesarini M, Malesci A, Danese S,Sorrentino D. The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. **Curr Drug Targets** *2012;13(10):1273-9*

239) **Fiorino G**, Peyrin-Biroulet L,Danese S. Bowel damage assessment in Crohn's disease by magnetic resonance imaging. **Curr Drug Targets** *2012;13(10):1300-7*

240) Danese S, **Fiorino G**,Rutella S. Regulatory T-cell therapy for Crohn's disease: in vivo veritas. **Gastroenterology** *2012;143(5):1135-1138*

241) **Fiorino G**, Peyrin-Biroulet L, Naccarato P, Szabo H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A,Danese S. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. **Inflamm Bowel Dis** *2012;18(6):1042-7*

242) De Cassan C, **Fiorino G**,Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? **Digestive diseases** *2012;30(4):368-75*

243) Fabro M, Szabo H, Terrosu G, Avellini C, Tabuso M, **Fiorino G**,Sorrentino D. Acute severe colitis: infliximab and/or cyclosporine? **Curr Drug Targets** *2011;12(10):1448-53*

244) **Fiorino G**, Cesarini M, Indriolo A,Malesci A. Mucosal healing in ulcerative colitis: where do we stand? **Curr Drug Targets** *2011;12(10):1417-23*

245) **Fiorino G**, Cesarini M,Danese S. Biological therapy for ulcerative colitis: what is after anti-TNF. **Curr Drug Targets** *2011;12(10):1433-9*

246) **Fiorino G**, Bonifacio C, Malesci A, Balzarini L,Danese S. MRI in Crohn's disease--current and future clinical applications. **Nat Rev Gastroenterol Hepatol** *2011;9(1):23-31*

247) **Fiorino G**, Bonifacio C, Peyrin-Biroulet L, Minuti F, Repici A, Spinelli A, Fries W, Balzarini L, Montorsi M, Malesci A,Danese S. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. **Inflamm Bowel Dis** *2011;17(5):1073-80*

248) Nunes T, **Fiorino G**, Danese S,Sans M. Familial aggregation in inflammatory bowel disease: is it genes or environment? **World J Gastroenterol** *2011;17(22):2715-22*

249) Spinelli A, Sacchi M, **Fiorino G**, Danese S,Montorsi M. Risk of postoperative recurrence and postoperative management of Crohn's disease. **World J Gastroenterol** *2011;17(27):3213-9*

250) Danese S, **Fiorino G**,Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. **Aliment Pharmacol Ther** *2011;34(1):1-10*

251) **Fiorino G**, Peyrin-Biroulet L, Repici A, Malesci A,Danese S. Adalimumab in ulcerative colitis: hypes and hopes. **Expert Opin Biol Ther** *2011;11(1):109-16*

252) Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF, Israeli E, Lakatos PL, **Fiorino G**, Cesarini M, Tsianos EV, Louis E,Ben-Horin S.

The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. **Aliment Pharmacol Ther** *2011;33(3):349-57*

253) Rahier JF, Papay P, Salleron J, Sebastian S, Ellul P, Teich N, **Fiorino G**, Blaha B, Garcia-Sanchez V, Haas T, Van Gossum A, Abitbol V, Yazdanpanah Y,Chaparro MC. Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. **Aliment Pharmacol Ther** *2011;33(4):499-500*

254) Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, Garcia-Sanchez V, Fries W, van Asseldonk DP, Farkas K, de Boer NK, Sipponen T, Ellul P, Louis E, Peake ST, Kopylov U, Maul J, Makhoul B, **Fiorino G**, Yazdanpanah Y, Chaparro M, European Cs,Colitis O. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. **Gut** *2011;60(4):456-62*

255) Rutella S, **Fiorino G**, Vetrano S, Correale C, Spinelli A, Pagano N, Arena V, Maggiano N, Repici A, Malesci A,Danese S. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. **The American journal of gastroenterology** *2011;106(4):762-70*

256) **Fiorino G**, Szabo H, Fries W, Malesci A, Peyrin-Biroulet L,Danese S. Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience. **Curr Med Chem** *2011;18(8):1230-8*

257) Danese S, **Fiorino G**, Angelucci E, Vetrano S, Pagano N, Rando G, Spinelli A, Malesci A,Repici A. Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study. **World J Gastroenterol** *2010;16(19):2396-400*

258) **Fiorino G**, Correale C, Fries W, Repici A, Malesci A,Danese S. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. **Expert Rev Clin Immunol** *2010;6(4):567-72*

259) Szabo H, **Fiorino G**, Spinelli A, Rovida S, Repici A, Malesci AC,Danese S. Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases. **Aliment Pharmacol Ther** *2010;31(2):189-201*

260) Sorrentino D, Paviotti A,**Fiorino G**. Anti-TNF's for postoperative recurrence in Crohn's disease: the if's and how's. **Curr Drug Targets** *2010;11(2):219-26*

261) **Fiorino G**, Rovida S, Correale C, Malesci A,Danese S. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? **Curr Drug Targets** *2010;11(2):249-60*

262) **Fiorino G**, Fries W, De La Rue SA, Malesci AC, Repici A,Danese S. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. **Curr Med Chem** *2010;17(17):1851-7*

263) **Fiorino G**, Allez M, Malesci A,Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. **Aliment Pharmacol Ther** *2009;29(9):921-7*

264) Cesarini M, Angelucci E, **Fiorino G**, Crudeli A, Vernia P,Caprilli R. Postoperative recurrence of Crohn's disease and videocapsule endoscopy: it is necessary to leave no stone unturned. **Inflamm Bowel Dis** *2008;14(8):1165-6*

Il sottoscritto FIORINO GIONATA, consapevole delle sanzioni penali richiamate dall'art. 76 del D.P.R. 28 dicembre 2000 n. 445 e s.m.i. in caso di dichiarazioni mendaci e della decadenza dei benefici eventualmente conseguiti al provvedimento emanato sulla base di dichiarazioni non veritiere, di cui all'art. 75 del richiamato D.P.R.; ai sensi e per gli effetti del D.P.R. 445/2000 e s.m.i., sotto la propria responsabilità dichiara che le informazioni presenti in questo documento sono corrispondenti al vero, ed autorizza il trattamento dei propri dati personali ai sensi del Dlgs 196 del 30 giugno 2003 e dell'art. 13 GDPR.